AXGN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$53.22median target· current $42.21 (+26.1%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 5000.00
EPS (TTM)$-0.670.0% YoY
Profit margin-13.4%HEALTHCARE
Market cap$2.27BMid cap
Valuation
- Forward P/E
- 5000.00
- PEG ratio
- 99.04
- P/B
- 8.86
- P/S (TTM)
- 9.03
- EV/EBITDA
- 4083.53
Profitability & growth
- ROE (TTM)
- -18.2%
- Operating margin
- -3.1%
- Revenue growth YoY
- 23.1%
- Dividend yield
- —
- Beta
- 1.09
Last earnings
Jul 29, 2026 · Estimate $-0.04 · Reported $-0.03
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Axogen Inc
Company profileAxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 13631 PROGRESS BOULEVARD, ALACHUA, FL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$2.27B
Shares outstanding$53.8M
52W high$46.95
52W low$12.75
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent